Neurological outcome of long-term glioblastoma survivors.

Détails

ID Serval
serval:BIB_1E2879532F95
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Neurological outcome of long-term glioblastoma survivors.
Périodique
Journal of Neuro-oncology
Auteur(s)
Hottinger A.F., Yoon H., DeAngelis L.M., Abrey L.E.
ISSN
1573-7373 (Electronic)
ISSN-L
0167-594X
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
95
Numéro
3
Pages
301-305
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
Extended survival of 3 or more years is rare in patients with glioblastoma (GBM) but is becoming more common. Clinical outcome has not been well studied. We reviewed GBM patients at Memorial Sloan-Kettering Cancer Center between 2001 and 2003 who were seen for two or more visits. Patient characteristics and long-term clinical outcomes were reviewed for patients who had survived 3 or more years following diagnosis. Thirty-nine (11%) of 352 GBM patients were identified as long-term survivors. Median survival was 9.15 years (range: 3-18 years). Median age was 47 years (range: 16-69); 13% were 65 years or older. Median KPS was 90 (range: 50-100). One long-term survivor underwent biopsy alone; 19 patients each had either complete or subtotal resection. All received focal radiotherapy (RT) with a median dose of 5940 cGy; 18% received concurrent temozolomide. Adjuvant chemotherapy was administered to 35 (90%). Twelve patients (31%) remained in continuous remission. Twenty-seven had tumor progression a median of 29.2 months after diagnosis (range: 1.2-167 months); 18 had multiple relapses. Median KPS at last follow-up was 70 (range: 40-100); 85% of long-term survivors had at least one significant neurologic deficit. Eleven (28%) had clinically significant RT-induced leukoencephalopathy, 9 (23%) developed RT necrosis and 9 (23%) treatment-related strokes. Treatment-related complications occurred a median of 2.7 years from diagnosis (range: 0.9-11.5 years). Long-term survivors remain rare, but are found across all age groups despite multiple recurrences; clinically significant delayed complications of treatment are common.
Mots-clé
Adolescent, Adult, Aged, Brain Neoplasms/mortality, Brain Neoplasms/surgery, Cognition Disorders/mortality, Databases, Factual, Follow-Up Studies, Glioblastoma/mortality, Glioblastoma/surgery, Humans, Karnofsky Performance Status, Middle Aged, Neoplasm Recurrence, Local/mortality, Quality of Life, Retrospective Studies, Survival Analysis, Survivors/statistics & numerical data, Young Adult
Pubmed
Création de la notice
19/02/2014 21:29
Dernière modification de la notice
20/08/2019 12:54
Données d'usage